Loading

Journal of Veterinary Medicine and Research

Chemical Mutagenesis, Isolation and Characterization of Non-Haemolytic

Research Article | Open Access

  • 1. Department of Molecular & Cellular Biology, University of Guelph, Canada
+ Show More - Show Less
Corresponding Authors
Reggie Y.C. Lo, Department of Molecular & Cellular Biology, University of Guelph, N1G 2W1, Ontario, Canada, Tel: 519-824-4120
ABSTRACT

A collection of non-haemolytic M. haemolytica mutants were generated by EMS (ethyl methanesulfonate) mutagenesis. Total proteins from these mutants were examined by Western immunoblot analysis using antibodies specific for the leukotoxin LktA. LktA was not detected in some of the mutants as expected; however, LktA was detected in several mutants in spite of a non-haemolytic phenotype. These mutants could have a defect in any one of the four genes, or elsewhere in the genome suggesting other factors may be required for fully functional leukotoxin production. The lktA gene from mutant 36 was isolated by PCR and sequenced. Mutant 36 was found to have a G-C to A-T substitution resulting in codon change from GAG to AAG and E470K amino acid substitution.

CITATION

Lo RYC, Williams A (2018) Chemical Mutagenesis, Isolation and Characterization of Non-Haemolytic. J Vet Med Res 5(7): 1146.

INTRODUCTION

Mannhemia haemolytica A1 (Mh) is a bovine pathogen that causes pneumonic pasteurellosis resulting in significant economic loss for the cattle industry [1,2]. The most important virulence factor produced by the bacterium is the leukotoxin (Lkt) which is a pore-forming cytolysin specific for bovine leukocytes but non-specific for erythrocytes resulting in cell lysis [3-6]. The non-specific binding and lysis of erythrocytes by Lkt produces a zone of clearance on blood agar plates. Lkt is produced by a four gene operon (lktCABD) which has been cloned and sequenced [7-9]. lktA codes for the structural protein LktA, lktC codes for an activator enzyme that is responsible for acylating LktA to its active form [7,8]. Together, lktB and lktD code for a secretion apparatus that secretes the toxin extracellularly [9].

The lkt operon showed extensive homology with the α-haemolysin (hly) operon in Escherichia coli [10]. Both toxins were found to have amino acid repeats within the toxin involved in binding of Ca+ [11]. The term RTX (repeats in the toxin) was coined to represent this family of toxins [12,13]. Subsequently, RTX toxins have been discovered in many bacterial pathogens such as: Actinobacillus pleuropneumoniae, Actinobacillus suis, Aggregatibacter actinomycetemcomitans, Bordetella pertussiss, Nesseria meningitidis [14-18]. Since then a lot of information has been gathered on the Mh leukotoxin and related RTX toxins, including binding specificity to target cells, pore forming activity, immunogenicity and the use of the toxin as vaccine components [13,19-22]. However, very little is known about the genetic mechanism(s) that regulate expression of the lkt operon. We have previously conducted studies which showed that temperature, pH, Fe2+ regulates lkt expression in Mh [23]. Studies by Highlander suggested bending of DNA at the lkt promoter, possibly involving IHF and a transcriptional factor [24-26]. Another report by Kolodrubetz on the human periodontal pathogen A. actinomycetemcomitans also suggested the interaction of a positively acting factor at its lkt promoter [27,28]. Therefore, it is very likely that some positively acting transcriptional factor is involved in expression of the lkt operon.

In this study, we attempted to search for genetic factor(s) involved in the regulation of expression of the Mhlkt operon. We utilized the phenotypic property of Mh which produces a zone of clearance on sheep’s blood agar plates due to haemolysis of red blood cells by the leukotoxin. Hence any mutation which abolishes Lkt activity or production will result in a non-haemolytic phenotype. The chemical mutagen ethyl methanesulfonate (EMS) was chosen to mutagenize Mh as this mutagen has been shown to induce primarily base-substitutions [29]. Here, we report the successful mutagenesis and isolation of non-haemolytic Mh mutants and the sequence analysis of mutant 36. We showed that mutant 36 harbours a G-C to A-T substitution resulting in an amino acid substitution in a highly conserved position of the toxin.

MATERIAL AND METHODS

Bacterial strains, culture conditions and EMS mutagenesis

Mh A1 is from our laboratory collection and is maintained on 5% sheep’s blood agar plates. For liquid cultures, bacterium is grown in BHI broth with shaking at 37C. The EMS mutagenesis procedure is modified from the protocol for E. coli according to Miller [30]. First, a kill/survival curve is established. Briefly, an overnight culture of Mh is sub-cultured 1/200 in 20 mL BHI broth and grown for 4 hr. The cells were collected by centrifugation, washed once in the same volume of 0.1 M MgSO4 and resuspended in half the volume (10 mL) of 0.2 M Tri-HCl (pH 7.5). Two mL aliquots were transferred into 15 mL sterile screw-cap plastic tubes and various amounts of EMS (Sigma Chemicals M0880-5G) were added. The tubes were placed horizontally and cells were mutagenized for 2 hr at 37 C with shaking. Afterwards, 0.1 mL was recovered for serial dilution and plated for survivors. One mL of the remaining culture was diluted into 9 mL BHIB and grown overnight. The recovered cultures were serially diluted, plated on sheep’s blood agar plates for non-haemolytic phenotype. Non-haemolytic colonies were picked and streaked for single colonies to confirm the mutant phenotype.

SDS-PAGE and Western immunoblot analysis

Total proteins from Mh cultures were examined by SDSPAGE and Western immunoblot using our standard laboratory procedure. An equal volume of overnight culture in BHI broth was mixed with 2X sample buffer, boiled and separated by SDSPAGE electrophoresis. Afterwards, the proteins were transferred to nitrocellulose membrane by electro-blotting. The proteins were immunostained with either monoclonal antibody 601 [31] or a polyclonal antibody [21] against LktA. The bound antibodies were then visualized with the appropriate second antibody (goat anti-mouse or goat anti-rabbit, respectively) conjugated to alkaline phosphatase and colour development accordingly. Some of the gels were also stained with Coomassie Blue after electrophoresis to provide visualization of proteins on the gel.

PCR amplification and sequence analysis

Total bacterial DNA was isolated using the QIAGEN Genomictip midi-prep according to the protocol. PCR was carried out using our standard laboratory conditions in an Eppendorf Mastercycler machine. Briefly, PCR were carried out in 25 µL reactions containing (final concentration) 1X PCR buffer, 2mM MgCl2 , 0.4 mM of each dNTP, 100 µM of both forward and reverse primers, 2.5 units of Platinum Taq DNA polymerase (Invitrogen) and 0.5 µL template DNA. A typical PCR cycle included: a onetime hotstart at 94 C for 2 minutes; 30 cycles of denaturation at 94 C for 1 minute, annealing at 50 C for 1 minute, extension at 72 C for3 minutes and a final extension at 72 C for 5 minutes. The primers (Table 1) were designed based on the published sequence of the lkt operon to amplify overlapping fragments to ensure the entire lktA region is sequenced. Three fragments of approximately 780 bp, 1.9 kbp and 1 kbp were amplified for sequence analysis. The PCR products were purified using the QIA quick PCR Purification Kit (QIAGEN), eluted in 30 µL double distilled H2 O and sent for sequence at the Genomic Facility, Advance Analysis Centre, University of Guelph, using the dye terminator sequencing method. The sequence data were examined with version 1.4 of the Finch TV software program. Finch TV was used to convert the sequence data into a FASTA file and compare to the published lkt sequence (Gene Bank access #M20730) using the Clustal W2 software program which highlights discrepancies in the aligned sequences.

 

RESULTS AND DISCUSSION

EMS mutagenesis

The base-substitution mutagen was used for this study to isolate mutant(s) that affect leukotoxin production and activity. This mutagen was selected in favor of other mutagens to avoid any gross alterations such as deletions or rearrangements in the DNA. A kill curve was established to determine the proper dosage for mutagenesis on Mh. It has been suggested that a 99.9% killing is the desired dose for EMS mutagenesis in E. coli [30]. The results in Figure (1) showed a kill curve based on three separate experiments and that a dose of 5 µL EMS was used for subsequent mutagenesis experiments. This protocol for EMS mutagenesis is simple and straight forward and can be adapted for mutagenesis with a suitable selection scheme.

Isolation of non-haemolytic mutants

The zone of clearance by Mh on blood agar plates gives it a simple phenotype to visualize non-haemolytic mutants. The results in Figure (2) showed the contracting non-haemolytic colony phenotype in comparison with the haemolytic parent. From four separate mutagenic experiments, thirty two mutants were recovered. Depending on when the mutagenic event took place during the overnight culture, it is possible that some of the mutants from each experiment are clones of each other. Mutants from separate experiments should be result of different mutagenic events.

Western Immnuoblot analysis of LktA

To determine whether the mutants are capable of producing the leukotoxin, total proteins from the mutants were examine by SDS-PAGE and Western immunoblot using antibodies against LktA. The results in Figure (3) showed that there is no LktA produced in mutants 1 and 17 as expected, but mutants11, 12, 14, 15, 34, 36 still produced LktA. Mutants 12, 14 and 34 appear to have a reduced amount of LktA, mutants 11, 15 and 36 exhibited similar levels of LktA compared to the parent. These blots are not quantitative and needs additional confirmation even though the results are reproducible. These mutants may have a defect in the lktA gene rendering it inactive.

Nucleotide sequence analysis

To determine if there is any mutation in the lkt promoter that could result in abolishing lkt expression, a 450 bp promoter region from seven mutants were amplified by PCR for sequence analysis. There was no alteration in these promoters (data not shown) suggesting the failure to produce Lkt is not due to a promoter mutation.

Since mutant 36 showed the presence of LktA, but a nonhaemolytic phenotype, the 3 kbp lktA gene from this mutant was amplified for sequence analysis. The result in Figure (4) showed that this mutant has a G-C to A-T transition. This base substitution resulted in a codon change from GAG to AAG and glutamic acid to lysine (E470K) amino acid substitution at residue 470 in LktA. This amino acid position is highly conserved in other RTX toxins [Table 2]. Interestingly, amino acid position 470 in Ap ApxIII and Aa Lkt has a glutamine and a lysine residue, respectively, instead of glutamic acid. Neither of these toxins exhibit haemolytic activity suggesting that E470 may be important for toxin activity against erythrocytes.

CONCLUSION

EMS mutagenesis is a simple and effective means of creating base-substitution mutations. The result from sequence analysis of mutant 36 showing a G-C to A-T transition is in agreement with the preferred mutagenic activity of EMS [29,31,32]. The glutamic acid residue at position 470 in LktA is a highly conserved position in RTX with haemolytic activity suggesting that it could be important for toxin activity against erythrocytes and warrants further investigation. Several mutants do not produce LktA as shown by Western Immunoblot analysis. These are mutants which could harbour defect(s) that abolished lkt expression. They could reside in genes that code for regulators that control expression of the lkt operon. They are candidates for additional analysis to determine the location of the mutation and the loci/ function affected. Further, any loci identified in these Mh mutants could have homologous loci in other RTX operons, giving it a wider implication on RTX regulation in these pathogens.

ACKNOWLEDGEMENTS

We thank Dr. Srikumaran for providing us with monoclonal antibody 601. We also thank Kyla Cochrane and Kelly Lo for assistance with the mutagenesis and Western immunoblot analysis respectively. This work is supported by a grant from the Natural Sciences and Engineering Research Council of Canada.

REFERENCES

1. Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997; 13: 367-377.

2. Yates WD. A review of infectious bovine rhinotricheitis, shipping fever pneumonia and viral-bacterial synergism in respiratory disease of cattle. Can J Comp Med. 1982; 46: 225-263.

3. Shewen PE, Wilkie BN. Cytotoxin of Pasteurella haemolytica acting on bovine leukocytes. Infect Immun. 1982; 35: 91-94.

4. Friend SC, Thomson RG, Wilkie BN. Pulmonary lesions induced by Pasteurella hemolytica in cattle. Can J Comp Med. 1977; 41: 219-223.

5. Lo RY. Genetic analysis of virulence factor of Pasteurella (Mannheimia) haemolytica A1. Vet Microbiol. 2001; 83: 23-35.

6. Lo RY. In Pathogenesis of Bacterial Infections in Animal. 2010; 347- 361.

7. Lo RY, Shewen PE, Strathdee CA, Greer CN. Cloning and expression of the leukotoxin gene of Pasteurellahaemolytica A1 in Escherichia coli K-12. Infect Immun. 1985; 50: 667-671.

8. Lo RY, Strathdee CA, Shewen PE. Nucleotide sequence of the leukotoxin genes of Pasteurella haemolytica A1. Infect Immun. 1987; 55: 1987-1996.

9. Strathdee CA, Lo RY. Cloning, nucleotide sequence, and characterization of genes encoding the secretion function of the Pasteurella haemolytica leukotoxin determinant. J Bacteriol. 1989; 171: 916-928.

10. Strathdee CA, Lo RY. Extensive homology between the leukotoxin of Pasteurella haemolytica A1 and the alpha-hemolysin of Escherichia coli. Infect Immun. 1987; 55: 3233-3236.

11. Welch RA. RTX toxin structure and function: a story of numerous anomalies and few analogies in toxin biology. Curr Top Microbiol Immunol. 2001; 257: 85-111.

12. Frey J, Kuhnert P. RTX toxins in Pasteurellaceae. Int J Med Microbiol. 2002; 292: 149-158.

13. Linhartová I, Bumba L, Mašín J, Basler M, Osi?ka R, Kamanová J, et al. RTX proteins: a highly diverse family secreted by a common mechanism. FEMS Microbiol Rev. 2010; 34: 1076-1112.

14. Linhartova I, Bumba L, Masia J, Basler M, Osicka R, Kamanov J, et al. RTX proteins: a highly diverse family secreted by a common mechanism. FEMS Micro Rev. 2010; 34: 1076-1112.

15. Kraig E, Dailey T, Kolodrubetz D. Nucleotide sequence of the leukotoxin gene from Actinobacillusactinomycetemcomitans: homology to the alpha-hemolysin/leukotoxin gene family. Infect Immun. 1990; 58: 920-929.

16. Frey J, Bosse JT, Chang YF, Cullen JM, Fenwick B, Gerlach GF, et al. Actinobacilluspleuropneumoniae RTX-toxins, uniform designation of haemolysins, cytolysins, pleurotoxin and their genes. J Gen Microbiol. 1993; 139: 1723-1728.

17. Burrows LL, Lo RY. Molecular characterization of an RTX toxin determinant from Actinobacillus suis. Infect Immun. 1992; 60: 2166- 2173.

18. Morova J, Osicka R, Masin J, Sebo P. RTX cytotoxins recognize beta2 integrin receptors through N-linked oligosaccharides. Proc Natl Acad Sci USA. 2008; 105: 5355-5360.

19. Thompson SA, Wang LL, West A, Sparling PF. Neisseria meningitides produces iron-regulated proteins related to the RTX family of exoproteins. J Bacteriol. 1993; 175: 811-818.

20. Menestrina G, Moser C, Pellet S, Welch R. Pore-formation by Escherichia colihemolysin (HlyA) and other members of the RTX toxin family. Toxicology. 1994; 87: 249-267.

21. Lally ET, Hill RB, Kieba IR, Korostoff J. The interaction between RTX toxins and target cells. Trends Microbiol. 1999; 7: 356-361.

22. Conlon JA, Shewen PE, Lo RY. Efficacy of recombinant leukotoxin in protection against pneumonic challenge with live Pasteurellahaemolytica A1. Infect Immun. 1991; 59: 587-591.

23. Lee RW, Strommer J, Hodgins D, Shewen PE, Lo RY. Towards development of an edible vaccine against bovine pneumonia pasteurellosis using transgenic white clover expressing a Mannheimiahemolytica A1 leukotoxin 50 fusion protein. Infect Immun. 2001; 69: 5786-5793.

24. Strathdee CA, Lo RY. Regulation of expression of the Pasteurella haemolytica leukotoxin determinant. J Bacteriol. 1989; 171: 5955- 5962.

25. Highlander SK, Wickersham EA, Garza O, Weinstock GM. Expression of the Pasteurella haemolytica leukotoxin is inhibited by a locus that encodes an ATP-binding cassette homolog. Infect Immun. 1993; 61: 3942-3951.

26. Highlander SK, Hang VT. A putative leucine zipper activator of Pasteurella haeomoytica leukotoxin transcription and the potential for modulation of its synthesis by slipped-strand mis pairing. Infect Immun. 1997; 65: 3970-3975.

27. Marciel AM, Highlander SK. Use of operon fusions in Mannheimia haemolytica to identify environmental and cis-acting regulators of leukotoxin transcription. Infect Immun. 2001; 69: 6231-6239.

28. Kolodrubetz D, Phillips L, Jacobs C, Burgum A, Kraig E. Anaerobic regulation of Aggregatibacter actinomycetemcomitans leukotoxin transcription is ArcA/FnrA-independent and requires a novel promoter element. Res Microbiol. 2003; 154: 645-653.

29. Kolodrubetz D, Phillips L, Burgum A. Repression of aerobic leukotoxin transcription by integration host factor in Aggregatibacter actinomycetemcomitans. Res Microbiol. 2010; 161: 541-548.

30. Burns PA, Allen FL, Glickman BW. DNA sequence analysis of mutagenicity and site specificity of ethyl methanesulfonate in Uvr+ and UvrB- strains of Escherichia coli. Genetics. 1986; 113: 811-819.

31. Miller JH. Experiments in Molecular Genetics. Cold Spring Harbour Press. 1972; 138.

32. Gentry MJ, Srikumaran S. Neutralizing monoclonal antibodies to Pasteurellahaemolyticaleukotoxin affinity-purify the toxin from culture supernatants. Microb Path. 1991; 10: 411-417.

Lo RYC, Williams A (2018) Chemical Mutagenesis, Isolation and Characterization of Non-Haemolytic. J Vet Med Res 5(7): 1146.

Received : 27 Aug 2018
Accepted : 24 Sep 2018
Published : 25 Sep 2018
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X